共 115 条
[1]
Hex N(2012)Estimating the current and future costs of type 1 and type 2 diabetes in the UK, including direct health costs and indirect societal and productivity costs Diabet Med 29 855-862
[2]
Bartlett C(2017)Overview of glucagon-like peptide-1 receptor agonists for the treatment of patients with type 2 diabetes Am Health Drug Benefits 10 178-188
[3]
Wright D(2008)Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes N Engl J Med 358 2560-2572
[4]
Taylor M(2008)10-year follow-up of intensive glucose control in type 2 diabetes N Engl J Med 359 1577-1589
[5]
Varley D(2020)Oral semaglutide versus empagliflozin, sitagliptin and liraglutide in the UK: long-term cost-effectiveness analyses based on the PIONEER clinical trial programme Diabetes Ther 11 259-277
[6]
Tran KL(2019)Evaluation of the long-term cost-effectiveness of once-weekly semaglutide versus dulaglutide for treatment of type 2 diabetes mellitus in the UK Diabetes Obes Metab 21 611-621
[7]
Park YI(2019)Management of patients with type 2 diabetes with once-weekly semaglutide versus dulaglutide, exenatide ER, liraglutide and lixisenatide: a cost-effectiveness analysis in the Danish setting Diabetes Ther 10 1297-1317
[8]
Pandya S(2019)Cost-effectiveness of DPP-4 inhibitor and SGLT2 inhibitor combination therapy for type 2 diabetes Am J Manag Care 25 231-238
[9]
Patel A(2018)The cost-effectiveness of a flash glucose monitoring system for management of patients with type 2 diabetes receiving intensive insulin treatment in Sweden Eur Endocrinol 14 80-85
[10]
MacMahon S(2004)The CORE diabetes model: projecting long-term clinical outcomes, costs and cost-effectiveness of interventions in diabetes mellitus (types 1 and 2) to support clinical and reimbursement decision-making Curr Med Res Opin 20 S5-26